Skip to main content
RXRX $2.49 -8.46%
RXRX logo
RXRX · Recursion Pharmaceuticals, Inc.
Track RXRX — free
$2.49 -0.23 (-8.46%) Play latest call Q2 2026 earnings call transcript
Market Cap
$1.53B
Shares
622.76M
Volume · Nov 20 29.66M Avg daily vol (3M) 24.44M
All webcasts

Earnings call · FY2026 Q3

Recursion Pharmaceuticals, Inc. (RXRX) Q3 2026 Earnings Call

Concluded Nov 3, 2026
Nov 3, 2026
Period
FY2026 Q3
Runtime
—
Sources
3 artifacts
Revenue $18.55M +258.5% YoY
Diluted EPS -$0.22
Gross margin · derived Q4 45.9% +229.7 pp YoY
Net income -$119.04M
Open full screen Slides 52 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 2, 2026
Recursion presented Phase 2 REC-4881 data showing a 47% median polyp burden reduction in FAP patients after 12 weeks. Also, 85% of evaluable patients remained below baseline 12 weeks off treatment.
10-Q report · filed Nov 2, 2026
Recursion reported further positive data from its Phase 1b/2 TUPELO trial of REC-4881 in FAP. After 12 weeks, 87% of patients (13 of 15) had reduced total polyp burden, with a 47% median reduction.

The audio replay and transcript follow the call.

Forward guidance

7 guided metrics

Management's latest ranges and targets are included below.

Research coverage

3 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Forward guidance

From the 8-K filed Nov 2, 2026.

Metric Guided
Cash operating expense
2026
up to $375M
Cash operating expense
2027
up to $360M
Cash operating expense guidance table
2026
up to $375M
Cash operating expense guidance table
2027
up to $360M
OpEx guidance
2026
up to $375M
Cash OpEx vs. 2024
2026
40%
OpEx guidance
2027
up to $360M

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

License And Service$18.05M +262.3% YoY
Grant$497,000 +158.9% YoY
Full-screen source Call document